Pharma BD Deal Intelligence
GEN positioned the deal positively as expanding Allergan's neurology depth, complementing Botox chronic migraine with an acute-migraine asset and adding MAP's…
Drugs.com chronicled Levadex's regulatory history — original March 2012 CRL, January 2013 Allergan acquisition, April 2013 second CRL — undercutting the…
Medscape reported Levadex received a Complete Response Letter from FDA in April 2013 citing CMC and third-party manufacturer inspection issues — the second…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Allergan to acquire MAP at $25/share (~$958M, 60% premium) to expand neurology/migraine franchise via Levadex orally inhaled DHE; cash tender + back-end merger.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Allergan plc / MAP Pharmaceuticals Inc. (this deal) | 2013 | $958M | 18 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Allergan plc / SkinMedica, Inc. | 2012 | $375M | 55 |
| Allergan plc / Inamed Corporation | 2005 | $3.2B | 50 |
| Allergan plc / Oculeve, Inc. | 2015 | $250M | 33 |
| Allergan plc / Zeltiq Aesthetics, Inc. | 2017 | $2.5B | 32 |
| Allergan plc / Kythera Biopharmaceuticals, Inc. | 2015 | $2.1B | 23 |
← Browse all deals · How we score deals
More: 2013 deals · Allergan plc deals · Neurology deals